{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:5462224",
      "entity_text" : "mg",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:49806720",
      "entity_text" : "alectinib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In enzymatic assays, alectinib was approximately 5 times more potent than crizotinib against ALK and inhibited most of the clinically observed acquired ALK resistance mutations to crizotinib.12 Alectinib showed superior efficacy and lower toxicity than crizotinib in the primary treatment of ALK positive NSCLC.13, 14 Therefore, we chose alectinib 300 mg twice daily as it is the approved dose for ALK positive NSCLC in Japan.14 Alectinib showed high antitumor efficacy in this case, and it appears to be an optimal bridging therapy to SCT for BV-refractory, ALK positive ALCL patients.",
  "reading_complete" : "2020-08-03T16:52:16Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T16:50:58Z",
  "trigger" : "inhibited",
  "evidence" : [ "alectinib was approximately 5 times more potent than crizotinib against ALK and inhibited most of the clinically observed acquired ALK resistance mutations to crizotinib.12 Alectinib showed superior efficacy and lower toxicity than crizotinib in the primary treatment of ALK-positive NSCLC.13, 14 Therefore, we chose alectinib 300 mg" ],
  "pmc_id" : "6935642",
  "score" : 0
}